Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
Seer, Inc. (SEER) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process REDWOOD CITY, Calif., October 29, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the S
How this was made
The 30-second read
Why it matters
The Special Committee’s conclusion and unanimous rejection directly changes the market’s probability-weighted M&A scenario for Seer and may shift focus back to product and commercial progress in proteomics.
Market read
Traders should reassess near-term takeover odds and the stock’s sensitivity to future strategic alternatives after the committee’s rejection of the two named bids.
What to watch
The release does not disclose whether management will actively solicit other bids or what specific strategic alternatives are next, leaving uncertainty around future M&A timing.
Background
Seer disclosed two unsolicited, non-binding proposals submitted in late July 2026 by the Radoff-JEC Group and by Seer’s CEO/Chair Omid Farokhzad, each including cash plus contingent value rights.
Ticker impact
Seer says its Special Committee concluded its review and unanimously rejected unsolicited acquisition proposals at $2.55 and $2.45 per share plus CVRs.
Likely modest downside or volatility as the market re-prices the probability of a near-term sale.
The filing is a primary disclosure of the committee’s decision to reject specific bids, which directly affects takeover expectations but does not provide new financial guidance or a new bid.
Market effects
Signals that proteomics platform companies may face active M&A interest, but this specific target remains independent.
Limited, company-specific Nasdaq-listed event.
Low, no cross-border transaction or regulatory action described.
Counterpoint
Rejection may clear the path for Seer to pursue alternative strategic options or strengthen its standalone valuation narrative, potentially supporting the stock if execution improves.
Key entities
- companySeer, Inc.
Nasdaq-listed proteomics company whose board special committee rejected unsolicited acquisition proposals.
- governanceSpecial Committee of Seer’s Board of Directors
Independent directors that evaluated unsolicited proposals and rejected them.
- acquirer_groupRadoff-JEC Group
Submitted an unsolicited, non-binding proposal to acquire Seer for $2.55 per share plus a contingent value right.
- executiveOmid Farokhzad
Seer Chair and CEO who submitted an unsolicited, non-binding proposal to acquire Seer for $2.45 per share plus two contingent value rights.

